Yao Liang Tang, M.D., Ph.D.
Biographical Sketch | Interests | Current Research | Major Publications
Ph.D., Fudan University, 2002
M.D., Shanghai 2nd Medical University, 1993
Biographical Sketch
Interests
coronary artery bypass
heart valve replacement
ascending artery replacement
Stem cell for myocardial repair
Gene therapy for myocardial protection
Heart transplantation
Current Research
Our lab has developed novel recombinant adeno-associated virus (rAAV) mediated regulated vector for in vivo gene transfer to achieve cardiac-specific, hypoxia-regulated expression and to explore the therapeutic potential of such physiological-regulated cardioprotective vector for preventing repeated bouts of attacks in diseases such as myocardial ischemia and stroke.
Another interest of our lab is vascular regeneration and myocardial regeneration. We have been attempting regeneration/repair of myocardial infarction and chronic heart failure with cytokine, which could mobilize circulating endothelial progenitor cells to ischemic myocardium, the results are remarkably promising. Recently we have identified novel resident cardiac stem cells (CSCs) from mouse. CSCs have been shown to possess multipotent capacity so that they could differentiate into cells of all three germ layers. We are now actively investigating various mechanisms which mediate therapeutic effect of stem cells in multiple cardiovascular diseases.
Major Publications
Tang YL, Zhao Q, Phillips M, et al. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regulatory Peptides, 2004, 117, 3-10.
Tang YL, Tang Y, Phillips M, et al. Preventing ischemic heart injury by vigilant plasmid mediated heme oxygenase-1 gene transfer. Hypertension, 2004, 43(4):746-51.
Tang YL, Qian K, Zhang YC, Shen LP, and Phillips M. Mobilizing of haematopoietic stem cells to ischemic myocardium by plasmid mediated stromal-cell-derived factor-1 (SDF-1) treatment. Regulatory Peptide, 2005. 125, 1-8
Tang YL, Autologous mesenchymal stem cells for post-ischemic myocardial repair, Molecular Cardiology: Methods and Protocols, Humana Press Inc., Totowa, NJ, 2005. 112, 183-92
Tang YL, Cellular therapy with autologous skeletal myoblasts for ischemic heart disease and heart failure, Molecular Cardiology: Methods and Protocols, Humana Press Inc., Totowa, NJ, 2005. 112, 193-204
Tang YL, Tang Y, Zhang YC, Agarwal A, Kasahara H, Qian K, Shen L, and Phillips MI. A Hypoxia-Inducible Vigilant Vector System for Activating Therapeutic Genes in Ischemia. Gene Therapy, 2005, 1-8.
Tang YL, Zhao Q, Qin X, Shen L, Cheng L, Ge J, and Phillips MI. Paracrine action enhance the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. The Annuals of Thoracic Surgery, 2005; 80:229-37.
Tang YL, Tang Y, Zhang YC, Qian K, Shen L and Phillips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated Heme Oxygenase-1 Vector. Journal of the American College of Cardiology, 2005 (In Press).
Tang YL, Qian K, Shen L and Phillips MI. Stromal cell-derived factor-1? gene therapy improves endothelial progenitor cells mobilization, myocardial neovascularization and cardiac function in chronic myocardial infarction. The Journal of Thoracic and Cardiovascular Surgery, 2005 (accepted).
Tang YL, Tang Y, Qian K, Shen L and Phillips MI. A vigilant, hypoxia-regulated heme oxygenase-1 gene vector in the heart, limits cardiac injury following ischemia-reperfusion in vivo. Journal of the American College of Cardiology, 2005 (In Revision).